This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Synageva BioPharma™ Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) WORLD Symposium™

Stocks in this article: GEVA

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid lipase deficiency (LAL Deficiency) data from oral and poster presentations at the LDN WORLD Symposium being held February 11-13 in San Diego, California.

Initial results with sebelipase alfa from an ongoing Phase 2/3 trial in infants with LAL Deficiency

As part of an oral presentation, Vassili Valayannopoulos, MD, Clinical Lead of the Lysosomal Storage Disease Clinic at Necker-Enfants Malades Hospital, Paris, France, presented initial results from the ongoing Phase 2/3 trial with sebelipase alfa in infants with LAL Deficiency. Data from nine infants enrolled in the trial as of January 2014 were presented at the meeting. The median age of infants at first infusion with sebelipase alfa was 3.0 months. Infants continuing in the trial demonstrate improvements in weight gain and other disease-related abnormalities after starting treatment with weekly infusions of sebelipase alfa (1-3 mg/kg). Six infants continue to receive treatment with sebelipase alfa, including three infants who met the primary endpoint of survival at 12 months of age and three infants who continue on treatment beyond six months of age. Two infants died shortly after starting the study due to rapidly progressive disease not related to the study drug (sebelipase alfa). One infant died shortly after starting the study due to a non-study related procedure and also unrelated to sebelipase alfa.

Adverse events with sebelipase alfa were mostly mild to moderate. Serious adverse events were mainly related to central line infections or hospitalizations for treatment with antibiotics. One patient experienced three related serious adverse events that included fever, malaise, and tachycardia developed during the infusion of sebelipase alfa. Four infants developed anti-drug antibodies and all four continue on infusions with sebelipase alfa at 3 mg/kg.

"Sebelipase alfa represents a potentially dramatic breakthrough for infants with LAL Deficiency who often die without treatment, usually before six months of age,” said Dr. Valayannopoulos. “As an enzyme replacement therapy, sebelipase alfa addresses the underlying cause of this rapidly progressive and often fatal disease and we are excited to continue dosing these infants as part of the ongoing Phase 2/3 clinical trial.”

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,677.90 +216.58 1.32%
S&P 500 1,950.82 +23.71 1.23%
NASDAQ 4,452.7920 +69.9450 1.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs